PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1811935
Original Article

Prevalence and Impact of TPMT and NUDT15 Gene Polymorphisms on Consolidation Phase Chemotherapy in Pediatric ALL

Authors

  • Abhilasha S. 

    1   Department of Medical Oncology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India

  • Niranjana Mahantashetti

    2   Department of Pediatrics, Jawaharlal Nehru Medical College, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India

  • Hershavardhini K.

    2   Department of Pediatrics, Jawaharlal Nehru Medical College, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India

  • Ashwini Doddannavar

    3   Department of Pharmacy Practice, KLE College of Pharmacy, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India

  • Vibha Bafna

    4   Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

  • Sandip Bartakke

    4   Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints
Preview

Abstract

Introduction

Acute lymphoblastic leukemia (ALL) is the most frequently occurring cancer in children, with cure rates exceeding 90%. The consolidation phase (CP) plays a vital role in lowering relapse rates. However, chemotherapy in this phase is commonly delayed due to toxicities related to 6-mercaptopurine (6-MP). The metabolism of 6-MP depends on enzymes encoded by the thiopurine S-methyltransferase (TPMT) and nucleoside diphosphate (NUDT15) (nudix hydrolase 15) genes. Inherited variations in these genes are known to impact drug metabolism, affecting effectiveness and toxicity.

Objectives

This study was conducted to determine the prevalence of notable TPMT and NUDT15 gene variants in pediatric patients with ALL from North Karnataka. It also aimed to evaluate the association of these polymorphisms with chemotherapy interruptions and related toxicities during the CP.

Materials and Methods

This longitudinal analysis included 106 patients newly diagnosed with ALL. Genetic screening for TPMT and NUDT15 mutations was carried out before the initiation of treatment. Data collected included the total 6-MP dose administered during CP, the number of delayed treatment days, frequency of febrile neutropenia (FN) episodes, and their duration.

Results

Over a period of 2.5 years, 106 patients were enrolled. The male-to-female ratio was 1.52, and the average age was 7.19 ± 4.08 years. Variants in NUDT15 and TPMT were found in 24.5 and 3.77% of cases, respectively. Those with genetic mutations had an average CP delay of 13.5 days and experienced more FN episodes, with a statistically significant difference (p = 0.002).

Conclusion

The frequency of TPMT and NUDT15 mutations in this group was higher than in previous Indian reports. These gene variants were linked to longer treatment delays and increased toxicity during CP. We propose that TPMT and NUDT polymorphism analysis should be performed upfront at diagnosis, so that consolidation delays can be minimized and toxicities can be reduced, which may improve the overall outcome.

Keywords

6-MP toxicity - chemotherapy delay - consolidation phase - NUDT polymorphism - TPMT polymorphism

Authors' Contributions

A.S. was responsible for data collection, establishing clinical diagnosis, planning investigations, management, and follow-up. N.M. provided guidance and support. H.K. was responsible for clinical care of the patient and writing the manuscript. A.D. was responsible for clinical care of the patient and data collection. V.B. and S.B. were responsible for planning the study and providing guidance in manuscript preparation.


Patient Consent

Patient consent has been received.




Publikationsverlauf

Artikel online veröffentlicht:
23. September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hayashi H, Makimoto A, Yuza Y. Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers (Basel) 2024; 16 (04) 723
    CrossrefPubMedSuche in Google Scholar
  • 2 Das N, Banavali S, Bakhshi S. et al. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials 2022; 23 (01) 102
    CrossrefPubMedSuche in Google Scholar
  • 3 Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 2018; 60 (01) 4-12
    CrossrefPubMedSuche in Google Scholar
  • 4 Mathisen MS, Kantarjian H, Thomas D, O'Brien S, Jabbour E. Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leuk Lymphoma 2013; 54 (12) 2592-2600
    CrossrefPubMedSuche in Google Scholar
  • 5 Relling MV, Gardner EE, Sandborn WJ. et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89 (03) 387-391
    CrossrefPubMedSuche in Google Scholar
  • 6 Singh M, Bhatia P, Khera S, Trehan A. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia. Leuk Res 2017; 62: 17-22
    CrossrefPubMedSuche in Google Scholar
  • 7 Dean L, Kane M. Mercaptopurine therapy and TPMT and NUDT15 genotype. In: Pratt VM, Scott SA, Pirmohamed M. et al., eds. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012
    Suche in Google Scholar
  • 8 Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in Middle Eastern children with acute lymphoblastic leukemia. Front Pharmacol 2019; 10: 916
    CrossrefPubMedSuche in Google Scholar
  • 9 Tanaka Y, Manabe A, Nakadate H. et al. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res 2012; 36 (05) 560-564
    CrossrefPubMedSuche in Google Scholar
  • 10 Pratt VM, Cavallari LH, Fulmer ML. et al. TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn 2022; 24 (10) 1051-1063
    CrossrefPubMedSuche in Google Scholar
  • 11 Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2019; 83 (02) 341-348
    CrossrefPubMedSuche in Google Scholar
  • 12 Pai AA, Mohan A, Benjamin ESB. et al. NUDT15 c.415C>T polymorphism predicts 6-MP induced early myelotoxicity in patients with acute lymphoblastic leukemia undergoing maintenance therapy. Pharm Genomics Pers Med 2021; 14: 1303-1313
    Suche in Google Scholar
  • 13 Sharma H, Wadhwa R. Mercaptopurine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021
    Suche in Google Scholar
  • 14 Du S, Huang X, He X. et al. Association of NUDT15 gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 2024; 109 (04) 1053-1068
    PubMedSuche in Google Scholar
  • 15 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 2011; 89 (05) 662-673
    CrossrefPubMedSuche in Google Scholar